Osteoporosis Management in Older Adults
|
|
- Curtis Shelton
- 6 years ago
- Views:
Transcription
1 Osteoporosis Management in Older Adults Angela M Cheung, MD, PhD, FRCPC, CCD Professor of Medicine, University of Toronto
2 Disclosures Relationship with Commercial Entities: Honoraria from: Amgen, Eli Lilly, Merck Grants to institution: Amgen, Eli Lilly Relationship with Non-commercial Entities: Chair, Osteoporosis Canada Scientific Advisory Council Chair, Canadian Bone Strength Working Group Director, CESHA at University of Toronto Director, Osteoporosis Program at University Health Network / Mount Sinai Hospital
3 Learning Objectives 1) Understand the epidemiology and risks associated with osteoporosis 2) Appreciate the latest developments in the pharmacological management of osteoporosis 3) Be aware of some of the current controversies around the treatment of osteoporosis
4 EPIDEMIOLOGY AND RISKS OF OSTEOPOROSIS
5 Annual incidence of common diseases Prevalence of Fractures in Canadian Women 200, ,000 * Canadian hip fractures from (1); Non-hip fracture data extrapolated from (2). Other represents non-osteoporotic fractures sites (humerus, clavicle, hands/fingers, patella, tibia, fibula) ,400 41,500 Other 80,000 38,900 Vertebral 32,700 Wrist 49,220 40,000 30,000 Hip 22, ,300 Pelvis Osteoporotic fractures 1,2 Heart Attack 3 Stroke 3 Breast Cancer 4 1. Leslie WD, et al. Osteoporos Int. 2010; 21: Burge J, et al. J Bone Miner Res. 2007;22: Canadian Institute for Health Information (2009) Health Indicators. 4. Canadian Cancer Society
6
7 Patients first response The floor was slippery I was clumsy The store owner should have cleaned up the spill It was an accident
8 % of all fractures that are fragility fractures 95% 90% 85% Overall: 81% 91.8% 80% 75% 75.7% 70% 65% 60% Age groups Bessette L, et al. Osteoporos Int 2008; 19:79-86.
9 % of patients being treated Post-fracture Care Gap: Comparison with Heart Attack How do we shift this paradigm? ~80% 20 ~15% 0 Anti-osteoporosis medication post fracture Beta-blockers post heart attack 1. Bessette L, et al. Osteoporos Int 2008; 19: Austin PC, et al. CMAJ 2008; 179(9):
10 In women with hip fractures: Fracture begets future fracture Deteriorated quality of life Long-term care admission Mortality 40% had prior fracture 1 40% need assistance walking 2 18% enter LTC 3 23% die within 1 year 4 Lifetime risk of hip fracture in women >50 is 12.1% 5 1. Hajcsar EE, et al. CMAJ 2000, 163: ; 2. Cooper C. Am J Med. 1997:103:12S-19S; 3. Jean et al. JBMR 2012 On-line September Ioannidis G, et al. CMAJ 2009;181: Hopkins et al Osteo Intl 2012; 23:
11 NEJM Case
12 PHARMACOLOGICAL MANAGEMENT
13 Hip fracture risk (% per 10 Years) Age & Risk of Fracture with Low BMD AGE Risk increases with age BMD T-score Kanis et al, Osteopor Int 2001
14 Two Tools for Fracture Risk Assessment These tools incorporate other risk factors for fracture in addition to BMD 1. OC Guidelines tool available at: 2. FRAX tool available at: 3. National Osteoporosis Foundation guidelines:
15 Femoral neck T-score Calculating 10-Year Absolute Fracture Risk for Postmenopausal Women: CAROC Increases to the next risk category Low risk (<10%) Prior fragility fracture after age 40 Prolonged corticosteroid therapy* Moderate risk (10-20%) High risk (> 20%) Prior hip or vertebral or >1 nonvertebral fragility fracture Age (years) Lumbar spine or total hip T-score -2.5: consider the individual to be at least at moderate risk Calibrated using Canadian fracture data and have been directly validated in Canadians 2 *At least three months cumulative use during the preceding year at a prednisone-equivalent dose 7.5 mg daily 1. Papaioannou A, et al. CMAJ. 2010;182: Leslie WD, et al. J Bone Miner Res. 2009;24:
16 High 10-Year Fracture Risk Those with: Hip Fractures Vertebral Fractures >2 fragility fractures >1 fragility fracture + steroid use
17 Femoral neck T-score CAROC Fracture Risk Assessment CAROC Assessment Tool Stratification Women (treatment naive) Most patients >age 75 are at Moderate to High risk of Fracture Low risk (<10%) based on age alone Moderate risk (10-20%) High risk (> 20%) Age (years) Hip / vertebral fracture High risk (> 20%) > 1 fragility fracture * At least three months cumulative use during the preceding year at a prednisone-equivalent dose 7.5 mg daily Papaioannou A, et al CMAJ 2010.
18 2010 Treatment Guidelines Low risk (<10%) Lifestyle Modification Moderate risk Lifestyle? Treat High risk (>20%) Treat Papaioannou A, et al. CMAJ. 2010;182:
19 Moderate Risk Treat if: Over 65 with wrist fracture Lumbar spine << Femoral neck T-score Medications (e.g. AI, ADT) Conditions (e.g. RA) Falls Patient preference
20 Consequences of Falls in Osteoporotic Patients Falls are a major contributor to fractures: Over 90% of hip fractures are the result of a fall Up to 14% of falls result in hip fractures Age 80 Age Grisso JA et al. N Engl J Med 1991; 324:
21 Pharmocological therapy First Line Therapies with Evidence for Fracture Prevention in Postmenopausal Women* Type of Fracture Antiresorptive Therapy Bisphosphonates Denosumab Raloxifene Estrogen** (Hormone Alendronate Risedronate Zoledronic therapy) Acid Bone Formation Therapy Teriparatide Vertebral Hip Non- Vertebral In clinical trials, non-vertebral fractures are a composite endpoint including hip, femur, pelvis, tibia, humerus, radius, and clavicle. * For postmenopausal women, indicates first line therapies and Grade A recommendation. For men requiring treatment, alendronate, risedronate, and zoledronic acid can be used as first line therapies for prevention of fractures [Grade D]. ** Estrogen or hormone therapy can be used as first line therapy in women with menopausal symptoms.
22 Special Considerations for the Geriatrics Population Falls risk Sarcopenia Poor Nutrition Poor Renal Function Multiple Comorbidities and Medications How many times has she fallen in the past 12 months?
23 Fall Prevention Strategies Assessment of fall risk: on admission/after a fall Patient education on risk of falls Environmental modification: reduction of fall hazards Reduce use of restraints for patients in care Adequate vitamin D Medication review Exercise: Tai chi, balance and strength training Hip protectors Compliant flooring Registered Nurse Association of Ontario (RNAO) Prevention of Falls and Falls injuries in Older Adults Recommendations.
24 Exercise To order: ext 5926
25 Assistive Devices
26 Different Types of Hip Protectors
27 Conditions
28 SmartCells: commercially available compliant floor for injury prevention SmartCells Installation of compliant flooring (SmartCells) in a demonstration bedroom of Delta View Rehabilitation Centre in Delta, BC
29 CURRENT CONTROVERSIES
30 CBC News closed with: People should consult their physicians before taking more than 800IU of vitamin D
31 CBS News: Vitamin D supplements won t help bones in healthy adults
32 Vitamin D Oversimplification of action of vitamin D Adequacy aiming for serum 25-hydroxyvitamin D levels: 75nmol/L (2010 OC guidelines) 50nmol/L (IOM guidelines for healthy adults) Reid meta-analysis: baseline mean serum 25- hydroxyvitamin D level > 50nmol/L in 15 studies Canadian Guidelines: 400IU 2000IU a day is safe
33
34 Calcium potential benefits US Preventive Services Task Force meta-analysis 2011: 16 RCTs 12% reduction in all fractures institionalized elderly RR= 0.71 (95%CI: ) community-dwelling RR=0.89 (95%CI: ) p=0.07 Tang et al meta-analysis 2007: 9 RCTs 10% reduction in all fractures Reid et al meta-analysis 2008: 3 RCTs 50% increase in hip fractures
35 Calcium potential harm Cardiovascular: Bolland 1 st meta-analysis 2010: 15 RCTs of Ca alone OR= 1.31 (95%CI: ) Bolland 2 nd meta-analysis 2011: 15 RCTs of Ca+/-D OR= 1.21 (95%CI: ) Wang et al meta-analysis 2010 (Included all WHI) Ca + D: RR = 1.04 (95%CI: ) Ca alone: RR = 1.14 (95%CI: )
36 Calcium Other side effects: constipation and bloating, constipation and bloating -- mild kidney stones: RR = 1.17 (dose-dependent) Current guidelines for total calcium intake per day : 2010 Osteoporosis Canada = 1200mg/day (diet + supplements) 2011 IOM = 1200mg/day (F>age50) = mg/day (M>age 50)
37 Osteonecrosis of the Jaw Exposed non-healing bone for 6 to 8 weeks
38 Incidence of BP associated ONJ (# cases/# pts -Rx filled) Overall number of patients ODB +PP Number of cancer patients (IV bisphosphonate) Brogan Rx data Number of patients with osteoporosis or metabolic bone disease Brogan Rx data Number in Ontario with bisphosphonate use at any time between Number of patients* with ONJ between ,513 2, , Three year cumulative incidence ~5 per 100,000 ~7 per 1,000 ~2 per 100,000 Average annual incidence ~2 per 100,000 ~2 per 1,000 ~1 per 100,000
39 Other risk factors Cancer (lymphoma, breast, prostate, multiple myeloma) Chemo and radiation High dose bisphosphonates for high calcium levels or for bone mets Steroids Diabetes Poor dental hygiene Invasive dental procedure
40 Atypical femur fractures (AFFs) low-trauma stress fractures in subtrochanteric or shaft region of the femur can be associated with bisphosphonate or denosumab therapy
41 Hip Fractures Subcapital Femoral neck Inter trochanteric Subtrochanteric
42 Radiographic Images of AFFs Transverse fracture line Transverse fracture line Focal Periosteal Reaction on Lateral cortex Subtrochanteric Mid-diaphyseal Oblique extension Medial spike ASBMR AFF Task Force Report, JBMR 2010, 25 (11): 2267
43 Imaging using other modalities Plain X-rays Bone Scan MRI DXA ASBMR AFF Task Force Report, JBMR 2010, 25 (11): 2282
44 Incidence of Complete AFFs Ontario CANADA Data Kaiser Permanente California Data ~1-2/1000 py after 6-7 years ~1/1000 py after years JAMA, February 23, 2011 Vol 305 (8): 783 JBMR,
45 Is long-term therapy still effective?* Is Is Long-term Long-term Therapy Therapy Still Still Effective?* Effective?* In In long-term long-term trials, trials, BMD BMD continued continued to to increase increase or or remained remained stable stable In long-term trials, BMD continued to increase or remained stable Pivotal Study Medication Pivotal Study Medication Extension Extension Risedronate Risedronate 1 VERT-MN 1 VERT-MN Treatment Treatment Duration Duration (yrs) (yrs) # of of Participants Participants % Change Change Lumbar Lumbar Spine BMD Spine BMD Ŧ Ŧ % Change Change Total Hip Total Hip BMD BMD Ŧ Ŧ Alendronate Alendronate 2 FLEX FLEX HORIZON Zoledronic HORIZON Zoledronic Acid Acid 3 (interim analysis (interim analysis of 9 year study) of year study) FREEDOM FREEDOM Denosumab Denosumab 4 (interim analysis (interim analysis of 10 year study) of 10 year study) * Not head to head analyses: Results cannot be compared due to differing study populations and methodologies. Ŧ * Represents Not head to % head change analyses: from BL Results of Pivotal cannot Trial. be compared due to differing study populations and methodologies. Ŧ Represents 10 % mg change dose from only. BL of Pivotal Trial. Represents 10 mg dose only. 1. Mellstrom D et al. Calcif Tissue Int 2004;75: Bone HG et al. N Engl J Med 2004;350: Black Mellstrom DM, et D et al. al. J Bone Calcif Miner Tissue Res. Int 2004;75: ; 27(2): Bone 4. Brown HG et JP, al. et N al. Engl 2011 J Med ACR 2004;350: Annual Meeting. Presentation L8 3. Black DM, et al. J Bone Miner Res. 2012; 27(2): Brown JP, et al ACR Annual Meeting. Presentation L8 1. Mellstrom D et al. Calcif Tissue Int 2004;75: Bone HG et al. N Engl J Med 2004;350: Black DM et al. J Bone Miner Res. 2012;27(2) Brown JP et al ACR Annual Meeting. Presentation L
46 Drug Holiday for low and moderate risk 2010 CAROC tool: Assessment of Basal 10-year Fracture Risk Women Men
47 Summary 1) the epidemiology and risks associated with osteoporosis 2) the latest developments in the pharmacological management of osteoporosis 3) the current controversies around the treatment of osteoporosis
48 Which of the conditions below is most common in women age 50 and over? a. Heart disease b. Breast cancer c. Stroke d. Osteoporotic fractures
49 Which of the conditions below is most common in women age 50 and over? a. Heart disease b. Breast cancer c. Stroke d. Osteoporotic fractures
50 Which of the patients below are at high risk of another major osteoporotic fracture in the next 10 years? a. Those with BMD T-score less than or equal to -2.5 and on prednisone 10mg a day for the past year b. Those with hip fractures irrespective of BMD c. Those with vertebral fractures irrespective of BMD d. Those with more than 1 fragility fracture irrespective of BMD e. All of the above
51 Which of the patients below are at high risk of another major osteoporotic fracture in the next 10 years? a. Those with BMD T-score less than or equal to -2.5 and on prednisone 10mg a day for the past year b. Those with hip fractures irrespective of BMD c. Those with vertebral fractures irrespective of BMD d. Those with more than 1 fragility fracture irrespective of BMD e. All of the above
52 Which of the following drug therapies is/ are first line therapy/ies for osteoporosis in the elderly? a. Oral bisphosphonates (daily, weekly, monthly) b. Intravenous bisphosphonate once a year c. Subcutaneous denosumab every 6 months d. Subcutaneous teriparatide every day for 2 years e. All of the above
53 Which of the following drug therapies is/ are first line therapy/ies for osteoporosis in the elderly? a. Oral bisphosphonates (daily, weekly, monthly) b. Intravenous bisphosphonate once a year c. Subcutaneous denosumab every 6 months d. Subcutaneous teriparatide every day for 2 years e. All of the above
54 WHI Calcium/Vit D 36,282 women age 50 to 79 yrs mg calcium with 400 IU Vit D 3 (CaD) versus placebo After 7 yrs: o non-significant reductions hip, clinical vertebral and total fracture. o CHD and cancer similar in the 2 groups Mean Ca intake in placebo group = 1154mg/ day
55 WHI Calcium/Vit D: 5 yrs after Trial 86% of participants CaD n=15025 and PBO n=14837 Fractures were self-reported Vertebral fractures: HR 0.87 (0.76, 0.98) Clinical vertebral fractures: HR 0.83 (0.71, 0.98) Hip fractures: HR 0.95 (0.78, 1.15) Total fractures: HR 1.00 (0.94, 1.06) No difference: total cancers, CVD, mortality
56
57 Questions? THANK YOU!
Fracture=Bone Attack:
Fracture=Bone Attack: Linking Hip Fractures to Osteoporosis Care Angela M. Cheung, MD, PhD, FRCPC Professor of Medicine, University of Toronto Potential Conflicts of Interests Industry Grants (to UHN)
More informationTreatments for Osteoporosis Expected Benefits, Potential Harms and Drug Holidays. Suzanne Morin MD FRCP FACP McGill University May 2014
Treatments for Osteoporosis Expected Benefits, Potential Harms and Drug Holidays Suzanne Morin MD FRCP FACP McGill University May 2014 Learning Objectives Overview of osteoporosis management Outline efficacy
More informationModule 5 - Speaking of Bones Osteoporosis For Health Professionals: Fracture Risk Assessment. William D. Leslie, MD MSc FRCPC
Module 5 - Speaking of Bones Osteoporosis For Health Professionals: Fracture Risk Assessment William D. Leslie, MD MSc FRCPC Case #1 Age 53: 3 years post-menopause Has always enjoyed excellent health with
More informationOsteoporosis: An Overview. Carolyn J. Crandall, MD, MS
Osteoporosis: An Overview Carolyn J. Crandall, MD, MS Osteoporosis: An Overview Carolyn J. Crandall, MD, MS Professor of Medicine David Geffen School of Medicine at UCLA Objectives Review osteoporosis
More informationUpdates in Osteoporosis. I have no conflicts of interest. What Would You Do? Mrs. C. What s New in Osteoporosis. Page 1
Updates in Osteoporosis Jeffrey A. Tice, MD Associate Professor of Medicine Division of General Internal Medicine, University of California, San Francisco I have no conflicts of interest What s New in
More informationA Review of Bone Health Issues in Oncology
A Review of Bone Health Issues in Oncology David L. Kendler MD FRCPC CCD Professor of Medicine (Endocrinology) University of British Columbia Vancouver Canada Disclosures David Kendler has received research
More informationWhat is Osteoporosis?
What is Osteoporosis? 2000 NIH Definition A skeletal disorder characterized by compromised bone strength predisposing a person to an increased risk of fracture. Bone strength reflects the integration of
More informationLearning Objectives. Controversies in Osteoporosis Prevention and Management. Definition. Presenter Disclosure Information.
4 4:45 pm Controversies in Osteoporosis Prevention and Management SPEAKER Carolyn Crandall, MD, MS Presenter Disclosure Information The following relationships exist related to this presentation: Carolyn
More informationHot Topics in Osteoporosis and Fracture Prevention
Hot Topics in Osteoporosis and Fracture Prevention Sid Feldman, MD CCFP (COE) FCFP Sandra Kim, MD, FRCPC November 15, 2018 Family Medicine Forum, Toronto Faculty/Presenter Disclosure Faculty: Sid Feldman
More informationPage 1. Diagnosis and Treatment of Osteoporosis: What s New and Controversial in 2018? What s New in Osteoporosis
Diagnosis and Treatment of Osteoporosis: What s New and Controversial in 2018? Douglas C. Bauer, MD Professor of Medicine and Epidemiology & Biostatistics University of California, San Francisco What s
More informationLearning Objectives. Controversies in Osteoporosis Prevention and Management. Etiology. Presenter Disclosure Information. Epidemiology.
12:45 1:30pm Controversies in Osteoporosis Prevention and Management SPEAKER Carolyn Crandall, MD, MS Presenter Disclosure Information The following relationships exist related to this presentation: Carolyn
More informationDiagnosis and Treatment of Osteoporosis: What s New and Controversial in ? What s New in Osteoporosis
Diagnosis and Treatment of Osteoporosis: What s New and Controversial in 2018-19? What s New in Osteoporosis The crisis in treatment and compliance Douglas C. Bauer, MD Professor of Medicine and Epidemiology
More informationOsteoporosis: Are your bones at risk of fracturing? Rachel Wallwork, MD Internal medicine resident Massachusetts General Hospital
Osteoporosis: Are your bones at risk of fracturing? Rachel Wallwork, MD Internal medicine resident Massachusetts General Hospital What is Osteoporosis? Osteoporosis causes bones to lose density, become
More informationDisclosures D. Black. Bisphosphonates: Background, Efficacy and Recent Controversies. Page 1. Research Funding: Novartis, Merck
Bisphosphonates: Background, Efficacy and Recent Controversies Disclosures D. Black Research Funding: Novartis, Merck Dennis M. Black, PhD Consulting: Amgen, Lilly, Zosano, Nycomed Dept. of Epidemiology
More informationAACE/ACE Osteoporosis Treatment Decision Tool
AACE/ACE Osteoporosis Treatment Decision Tool What is Osteoporosis? OSTEOPOROSIS is defined as reduced bone strength leading to an increased risk of fracture. Osteoporosis, or porous bones, occurs when
More informationOptimizing Osteoporosis Management Dr. Philip A. Baer Seacourses Asia CME December 2017
Optimizing Osteoporosis Management Dr. Philip A. Baer Seacourses Asia CME December 2017 Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored,
More informationWho cares about fractures! is more important. October 3, 2014 CSIM Workshop Brian Wirzba, MD, FRCPC, FACP Clinical Professor Grey Nuns Hospital
Isn t Osteoporosis just a T Score less than 2.5?? Who cares about fractures! is more important. Why do I need to know this? October 3, 2014 CSIM Workshop Brian Wirzba, MD, FRCPC, FACP Clinical Professor
More informationPage 1. New Developments in Osteoporosis. What s New in Osteoporosis
New Developments in Osteoporosis Eliseo J. Pérez-Stable MD Professor of Medicine Division of General Internal Medicine Department of Medicine July 4, 2013 Declaration of full disclosure: No conflict of
More informationRefracture Prevention The Role of Primary Care
MonashHealth Refracture Prevention The Role of Primary Care Professor Peter R Ebeling AO MBBS MD FRACP Head, Department of Medicine School for Clinical Sciences Monash Health Translation Precinct Monash
More informationOsteoporosis Management
Osteoporosis Management Lisa Voss PA C, CCD Laura Frontiero NP C, CCD Kaiser Healthy Bones Program San Diego Disclosures: Nothing to disclose www.zazzle.com 1 Overview How to diagnose Osteoporosis FRAX
More informationOsteoporosis Case Studies
2019 Endocrine and Diabetes Symposium for Primary Care Providers Osteoporosis Case Studies Joseph B Hawkins, Jr., MD, FACE Assistant Clinical Professor of Medicine, UCSF Founder, Sierra Endocrine Associates
More informationAdvanced medicine conference. Monday 20 Tuesday 21 June 2016
Advanced medicine conference Monday 20 Tuesday 21 June 2016 Osteoporosis: recent advances in risk assessment and management Juliet Compston Emeritus Professor of Bone Medicine Cambridge Biomedical Campus
More informationCalcium, Vitamin D and Bisphosphonates: Disclosures. Benefits, Risks and Drug Holiday. Calcium YES or NO? Calcium Bad News!!
Calcium, Vitamin D and Bisphosphonates: Benefits, Risks and Drug Holiday Disclosures I am disclosing financial relationships as follows: Global Advisory Boards: Amgen, Lilly, Merck, Novartis Research grants:
More informationDisclosures. Diagnostic Challenges in Osteoporosis: Whom To Treat 9/25/2014
Disclosures Diagnostic Challenges in Osteoporosis: Whom To Treat Ethel S. Siris, MD Columbia University Medical Center New York, NY Consultant on scientific issues for: AgNovos Amgen Eli Lilly Merck Novartis
More informationOsteoporosis Agents Drug Class Prior Authorization Protocol
Osteoporosis Agents Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review of
More informationPage 1. Updates in Osteoporosis. I have no conflicts of interest. What is osteoporosis? What s New in Osteoporosis
Updates in Osteoporosis Jeffrey A. Tice, MD Professor of Medicine Division of General Internal Medicine, University of California, San Francisco I have no conflicts of interest What s New in Osteoporosis
More informationOsteoporosis. A Silent Killer. David A. Chappell, MD Endocrinology Private Practice Petaluma, California
Osteoporosis A Silent Killer David A. Chappell, MD Endocrinology Private Practice Petaluma, California Relevant Disclosures Speakers Bureau Astra Zeneca Boehringer Ingelheim AACE/ACE Guidelines American
More informationPage 1. Current and Emerging Strategies What s New in Osteoporosis. Osteoporosis. What is Osteoporosis? Traditional Risk Factors for Fracture
Current and Emerging Strategies for Osteoporosis What s New in Osteoporosis Risk stratification Douglas C. Bauer, MD University of California, San Francisco Under recognition and poor compliance New potential
More informationOsteoporosis. The Silent Killer. Joseph B. Hawkins, Jr., MD, FACE Sierra Endocrine Associates Fresno, California
Osteoporosis The Silent Killer Joseph B. Hawkins, Jr., MD, FACE Sierra Endocrine Associates Fresno, California Disclosures Speakers Bureau Amgen AACE/ACE Guidilines American Association of Clinical Endocrinologist
More informationCASE 1 WHY IS IT IMPORTANT TO TREAT? FACTS CONCERNS
4:30-5:15pm Ask the Expert: Osteoporosis SPEAKERS Silvina Levis, MD OSTEOPOROSIS - FACTS 1:3 older women and 1:5 older men will have a fragility fracture after age 50 After 3 years of treatment, depending
More informationMonitoring Osteoporosis Therapy
Monitoring Osteoporosis Therapy SUZANNE MORIN DEPT OF MEDICINE, DIVISION OF GENERAL INTERNAL MEDICINE, MUHC CENTRE FOR OUTCOMES RESEARCH AND EVALUATION, RI MUHC November 2017 Conflict of Interest Disclosures
More informationBalancing the Risks and Benefits of Osteoporosis Treatment: part I: 3 to 5 years treatment
Balancing the Risks and Benefits of Osteoporosis Treatment: part I: 3 to 5 years treatment Dennis M. Black, PhD Department of Epidemiology and Biostatistics, UCSF Financial Disclosures (past 3 years) -Consulting
More information2017 Santa Fe Bone Symposium McClung
217 Santa Fe Bone Symposium Insights into the Use of Anti-remodeling and Anabolic Agents for Osteoporosis Developing a Long-term Management Plan Michael R., MD, FACP Oregon Osteoporosis Center Portland,
More informationCurrent and Emerging Strategies for Osteoporosis
Current and Emerging Strategies for Osteoporosis I have nothing to disclose. Anne Schafer, MD Assistant Professor of Medicine Division of Endocrinology & Metabolism December 12, 2014 Outline Osteoporosis
More informationDrug Intervals (Holidays) with Oral Bisphosphonates
Drug Intervals (Holidays) with Oral Bisphosphonates Rizwan Rajak Consultant Rheumatologist & Lead for Osteoporosis GP Postgraduate Meeting April 2018 Contents Case presentation Pathway for Bisphosphonate
More informationUpdates in Osteoporosis
Updates in Osteoporosis Jeffrey A. Tice, MD Associate Professor of Medicine Division of General Internal Medicine, University of California, San Francisco I have no conflicts of interest What s New in
More informationOsteoporosis/Fracture Prevention
Osteoporosis/Fracture Prevention NATIONAL GUIDELINE SUMMARY This guideline was developed using an evidence-based methodology by the KP National Osteoporosis/Fracture Prevention Guideline Development Team
More informationOsteoporosis: A Tale of 3 Task Forces!
Osteoporosis: A Tale of 3 Task Forces! Robert A. Adler, MD McGuire Veterans Affairs Medical Center Virginia Commonwealth University Richmond, Virginia, USA Disclosures The opinions are those of the speaker
More informationDownload slides:
Download slides: https://www.tinyurl.com/m67zcnn https://tinyurl.com/kazchbn OSTEOPOROSIS REVIEW AND UPDATE Boca Raton Regional Hospital Internal Medicine Conference 2017 Benjamin Wang, M.D., FRCPC Division
More informationCurrent and Emerging Approaches for Osteoporosis
Current and Emerging Approaches for Osteoporosis Douglas C. Bauer, MD Professor of Medicine and Epidemiology & Biostatistics University of California, San Francisco No Disclosures What s New in Osteoporosis
More informationNew Developments in Osteoporosis: Screening, Prevention and Treatment
Osteoporosis: Overview New Developments in Osteoporosis: Screening, Prevention and Treatment Judith Walsh, MD, MPH Departments of Medicine and Epidemiology and Biostatistics UCSF Definitions Risk factors
More informationAn Update on Osteoporosis Treatments
An Update on Osteoporosis Treatments Dr Mike Stone University Hospital Llandough Treatments for osteoporosis Calcium and vitamin D HRT Raloxifene Etidronate Alendronate Risedronate Ibandronate (oral and
More informationOsteoporosis Update. Greg Summers Consultant Rheumatologist
Osteoporosis Update Greg Summers Consultant Rheumatologist DEFINITION OSTEOPOROSIS is LOW BONE MASS (& micro-architectural deterioration) causing AN INCREASED RISK OF FRACTURE 23 years 82 years 23 y/o
More informationTalking to patients with osteoporosis about initiating therapy
Talking to patients with osteoporosis about initiating therapy Deborah Sellmeyer, MD Director, Johns Hopkins Metabolic Bone Center Dept of Medicine, Division of Endocrinology Disclosure DSMB member for
More information9/9/2015 OSTEOPOROSIS WHAT S NEW AND ON THE HORIZON IN SCREENING, DRUG HOLIDAYS, SUPPLEMENTS, CONSERVATIVE THERAPY DISCLOSURES
OSTEOPOROSIS WHAT S NEW AND ON THE HORIZON IN SCREENING, DRUG HOLIDAYS, SUPPLEMENTS, CONSERVATIVE THERAPY Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO DISCLOSURES Stock options/holdings,
More informationOsteoporosis Clinical Guideline. Rheumatology January 2017
Osteoporosis Clinical Guideline Rheumatology January 2017 Introduction Osteoporosis is a condition of low bone mass leading to an increased risk of low trauma fractures. The prevalence of osteoporosis
More informationTREATMENT OF OSTEOPOROSIS HOLIDAYS OR NO HOLIDAYS? Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO
TREATMENT OF OSTEOPOROSIS HOLIDAYS OR NO HOLIDAYS? Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO DISCLOSURES Honoraria: Amgen, Merck, Shire Consulting : AbbVie, Amgen, Merck,
More informationPage 1. Current and Emerging Strategies for Osteoporosis. Osteoporosis Warm-Up: Which of the Following is True?
Current and Emerging Strategies for Osteoporosis Douglas C. Bauer, MD Professor of Medicine and Epidemiology & Biostatistics University of California, San Francisco No Disclosures Osteoporosis Warm-Up:
More informationOSTEOPOROSIS: PREVENTION AND MANAGEMENT
OSTEOPOROSIS: OVERVIEW OSTEOPOROSIS: PREVENTION AND MANAGEMENT Judith Walsh, MD, MPH Departments of Medicine and Epidemiology and Biostatistics UCSF Definitions Key Risk factors Screening and Monitoring
More information1
www.osteoporosis.ca 1 2 Overview of the Presentation Osteoporosis: An Overview Bone Basics Diagnosis of Osteoporosis Drug Therapies Risk Reduction Living with Osteoporosis 3 What is Osteoporosis? Osteoporosis:
More informationDartmouth General Hospital Fracture Liaison Service. Carla Purcell BScN, RN, CMSN(C) Fracture Navigator
Dartmouth General Hospital Fracture Liaison Service Carla Purcell BScN, RN, CMSN(C) Fracture Navigator Acknowledgments Dr. Diane Theriault Heather Francis DGH Ortho Clinics Points to Cover Osteoporotic
More informationLong-term Osteoporosis Therapy What To Do After 5 Years?
Long-term Osteoporosis Therapy What To Do After 5 Years? Developing a Long-term Management Plan North American Menopause Society Philadelphia, PA October 11, 2017 Michael R. McClung, MD, FACP Institute
More informationDifferentiating Pharmacological Therapies for Osteoporosis
Differentiating Pharmacological Therapies for Osteoporosis Socrates E Papapoulos Department of Endocrinology & Metabolic Diseases Leiden University Medical Center The Netherlands Competing interests: consulting/speaking
More informationPage 1. Osteoporosis Warm-Up: Which of the Following is True? Diagnosis and Treatment of Osteoporosis: What is New in What s New in Osteoporosis
Diagnosis and Treatment of Osteoporosis: What is New in 2017 Douglas C. Bauer, MD Professor of Medicine and Epidemiology & Biostatistics University of California, San Francisco No Disclosures Osteoporosis
More informationAssessment and Treatment of Osteoporosis Professor T.Masud
Assessment and Treatment of Osteoporosis Professor T.Masud Nottingham University Hospitals NHS Trust University of Nottingham University of Derby University of Southern Denmark What is Osteoporosis? Osteoporosis
More informationManagement of postmenopausal osteoporosis
Management of postmenopausal osteoporosis Yeap SS, Hew FL, Chan SP, on behalf of the Malaysian Osteoporosis Society Committee Working Group for the Clinical Guidance on the Management of Osteoporosis,
More informationCurrent Issues in Osteoporosis
Current Issues in Osteoporosis California AACE 18TH Annual Meeting & Symposium Marina del Rey, CA September 15, 2018 Michael R. McClung, MD, FACP,FACE Director, Oregon Osteoporosis Center Portland, Oregon,
More informationControversies in Osteoporosis Management
Controversies in Osteoporosis Management 2018 Northwest Rheumatism Society Meeting Portland, OR April 28, 2018 Michael R. McClung, MD, FACP Director, Oregon Osteoporosis Center Portland, Oregon, USA Institute
More informationConflict of Interest Jonathan D. Adachi
Conflict of Interest Jonathan D. Adachi Consultant/Speaker Actavis Amgen Eli Lilly Merck Clinical Trials Amgen Eli Lilly Merck Novartis Stock None to declare Current Controversies In Osteoporosis Provided
More informationOsteoporosis: How to Manage Long- Term Use of Bisphosphonates AKA Now What? David E Feinstein, DO, CCD November 15 th, 2017
Osteoporosis: How to Manage Long- Term Use of Bisphosphonates AKA Now What? David E Feinstein, DO, CCD November 15 th, 2017 Introduction A fracture due to OP occurs every 3 seconds around the world. 1
More informationTask Force Co-Chairs. Members
Managing Osteoporosis Patients After Long-Term Bisphosphonate Treatment Report of a Task Force* of the American Society for Bone and Mineral Research Robert A. Adler, MD Task Force Co-Chairs Ghada El-Hajj
More informationMen and Osteoporosis So you think that it can t happen to you
Men and Osteoporosis So you think that it can t happen to you Jonathan D. Adachi MD, FRCPC Alliance for Better Bone Health Chair in Rheumatology Professor, Department of Medicine Michael G. DeGroote School
More informationACP Colorado-Evidence Based Management of Osteoporosis
ACP Colorado-Evidence Based Management of Osteoporosis Micol S. Rothman, MD Associate Professor of Medicine and Radiology Clinical Director Metabolic Bone Program University of Colorado School of Medicine
More informationJuly 2012 CME (35 minutes) 7/12/2016
Financial Disclosures Epidemiology and Consequences of Fractures Advisory Board: Amgen Janssen Pharmaceuticals Inc. Ann V. Schwartz, PhD Department of Epidemiology and Biostatistics UCSF Outline Osteoporotic
More informationOsteoporosis. Overview
v2 Osteoporosis Overview Osteoporosis is defined as compromised bone strength that increases risk of fracture (NIH Consensus Conference, 2000). Bone strength is characterized by bone mineral density (BMD)
More informationScreening Guidelines: Women
The Situation 1 in 2 postmenopausal women and 1 in 5 older men will have an osteoporosis-related fracture in their lifetimes Osteoporosis Definition NIH Consensus Conference A skeletal disorder characterized
More informationOSTEOPOROSIS IN MEN. Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO
OSTEOPOROSIS IN MEN Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO DISCLOSURES Speakers Bureau: Amgen, Radius Consultant: Abbvie, Amgen, Janssen, Radius, Sanofi Watts NB et
More informationOsteoporosis Update: Treatments and Controversies
Osteoporosis Update: Treatments and Controversies Sabrina Gill MD MPH FRCPC Clinical Professor, UBC St. Paul s Hospital Images provided by D. Dempster, PhD, Helen Hayes Hospital, NY Honoraium for CME and
More informationOsteoporosis Update. Case 2. Case 1: Monday morning, 8:15
Osteoporosis Update Laura E. Ryan, MD Assistant Director for Special Programs Center for Women s Health Clinical Assistant Professor of Medicine Division of Endocrinology, Diabetes and Metabolism The Ohio
More informationUsing the FRAX Tool. Osteoporosis Definition
How long will your bones remain standing? Using the FRAX Tool Gary Salzman M.D. Director Banner Good Samaritan/ Hayden VAMC Internal Medicine Geriatric Fellowship Program Phoenix, Arizona Using the FRAX
More information8/6/2018. Glucocorticoid induced osteoporosis: overlooked and undertreated? Disclosure. Objectives. Overview
Disclosure Glucocorticoid induced osteoporosis: overlooked and undertreated? I have no financial disclosure relevant to this presentation Tasma Harindhanavudhi, MD Division of Diabetes and Endocrinology
More informationPharmacy Management Drug Policy
SUBJECT: - Forteo (teriparatide), Prolia (denosumab), Tymlos (abaloparatide) POLICY NUMBER: Pharmacy-35 EFFECTIVE DATE: 9/07 LAST REVIEW DATE: 9/29/2017 If the member s subscriber contract excludes coverage
More informationBreast Cancer and Bone Loss. One in seven women will develop breast cancer during a lifetime
Breast Cancer and Bone Loss One in seven women will develop breast cancer during a lifetime Causes of Bone Loss in Breast Cancer Patients Aromatase inhibitors Bil Oophorectomy Hypogonadism Steroids Chemotherapy
More informationSpongeBone Menopants*
SpongeBone Menopants* Adam Fershko, MD, FACP Kettering Health Network *Postmenopausal Osteoporosis Objectives O Epidemiology O Clinical significance O Pathophysiology O Screening and Diagnosis O Treatment
More informationOsteoporosis/Fracture Prevention Clinician Guide SEPTEMBER 2017
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Osteoporosis/Fracture Prevention Clinician Guide SEPTEMBER 2017 Introduction This Clinician Guide was developed to assist Primary Care physicians
More informationMeta-analysis: analysis:
1 Diabetes and TZDs: Risk Factors for Fracture Ann Schwartz, PhD Dept. of Epidemiology and Biostatistics University of California San Francisco July 2010 Osteoporosis CME Presenter Disclosure Information
More informationJohn J. Wolf, DO Family Medicine
John J. Wolf, DO Family Medicine Objectives: 1. Review incidence & Risk of Osteoporosis 2.Review indications for testing 3.Review current pharmacologic & Non pharmacologic Tx options 4.Understand & Utilize
More informationAN OVERVIEW of TREATMENT: WHO and WHEN to TREAT
AN OVERVIEW of TREATMENT: WHO and WHEN to TREAT Dolores Shoback, MD Professor of Medicine, UCSF San Francisco VA Medical Center July 16, 21 ~ QUESTIONS ~ Who should receive therapy to prevent fractures?
More informationOsteoporosis - New Guidelines. Michelle Glass B.Sc. (Pharm) June 15, 2011
Osteoporosis - New Guidelines Michelle Glass B.Sc. (Pharm) June 15, 2011 Outline What is Osteoporosis? Who is at risk? What treatments are available? Role of the Pharmacy technician Definition of Osteoporosis
More informationNAMS Practice Pearl. Use of Drug Holidays in Women Taking Bisphosphonates. Released April 1, 2013
NAMS Practice Pearl Use of Drug Holidays in Women Taking Bisphosphonates Released April 1, 2013 Dima L. Diab, MD 1, and Nelson B. Watts, MD 2 ( 1 Cincinnati VA Medical Center, Cincinnati, OH, 2 Mercy Health
More informationOsteoporosis Screening and Treatment in Type 2 Diabetes
Osteoporosis Screening and Treatment in Type 2 Diabetes Ann Schwartz, PhD! Dept. of Epidemiology and Biostatistics! University of California San Francisco! October 2011! Presenter Disclosure Information
More informationPostmenopausal Osteoporosis
Osteoporosis Products Available in Canada for the Treatment and Prevention of Postmenopausal Osteoporosis Physician Desk Reference - 2nd Edition A clinical resource provided to you by: The Society of Obstetricians
More informationFrom Fragile to Firm. Monika Starosta MD. Advocate Medical Group
From Fragile to Firm Monika Starosta MD Advocate Medical Group Bone Remodeling 10% remodeled each year Calcium homoeostasis Maintain Mechanical strength Replace Osteocytes Release Growth Factors Bone remodeling
More informationOsteoporosis challenges
Osteoporosis challenges Osteoporosis challenges Who should have a fracture risk assessment? Who to treat? Drugs, holidays and unusual adverse effects Fracture liaison service? The size of the problem 1
More informationAtypical Femoral Fractures Insights and Enigmas
Atypical Femoral Fractures Insights and Enigmas Madhu Mehta, M.D. Clinical Asst. Prof. of Medicine Department of Immunology/Rheumatology The Ohio State University Abreviations used TFF- Typical femoral
More informationClinician s Guide to Prevention and Treatment of Osteoporosis
Clinician s Guide to Prevention and Treatment of Osteoporosis Published: 15 August 2014 committee of the National Osteoporosis Foundation (NOF) Tipawan khiemsontia,md outline Basic pathophysiology screening
More informationEpidemiology and Consequences of Fractures
Epidemiology and Consequences of Fractures Ann V. Schwartz, PhD Department of Epidemiology and Biostatistics UCSF Financial Disclosures Advisory Board: Amgen Research Support: Hologic 24July12 1 Outline
More information11/4/2018. Osteoporosis Update. ACP Oregon Chapter November 9 th, 2018 Sarah Hopkins Providence Medical Group Endocrinology East. No disclosures.
Osteoporosis Update ACP Oregon Chapter November 9 th, 2018 Sarah Hopkins Providence Medical Group Endocrinology East No disclosures. 1 Goals Review screening recommendations and workup of secondary causes
More informationAACE. Orlando Drug Holidays. Disclosures. Advisory boards: Alexion, Amgen, Lilly, Merck, Radius Health
AACE Orlando 2016 Drug Holidays Disclosures Advisory boards: Alexion, Amgen, Lilly, Merck, Radius Health Scientific grants: Alexion, Amgen, Immunodiagnostics, Lilly, Merck, Regeneron, Radius Health, Roche
More informationOsteoporosis: A Tale of 3 Task Forces!
Osteoporosis: A Tale of 3 Task Forces! Robert A. Adler, MD McGuire Veterans Affairs Medical Center Virginia Commonwealth University Richmond, Virginia, USA Disclosures The opinions are those of the speaker
More informationTherapeutic Updates in the Prevention and Treatment of Osteoporosis
Therapeutic Updates in the Prevention and Treatment of Osteoporosis 2013 Fall Managed Care Forum Las Vegas November 15, 2013 Steven T Harris MD FACP Clinical Professor of Medicine University of California,
More informationPharmacy Management Drug Policy
SUBJECT: - Forteo (teriparatide), Prolia (denosumab), Tymlos (abaloparatide), Boniva injection (Ibandronate) POLICY NUMBER: Pharmacy-35 EFFECTIVE DATE: 9/07 LAST REVIEW DATE: 10/15/2018 If the member s
More informationOsteoporosis: current treatment and future prospects. Juliet Compston Professor Emeritus of Bone Medicine Cambridge Biomedical Campus
Osteoporosis: current treatment and future prospects Juliet Compston Professor Emeritus of Bone Medicine Cambridge Biomedical Campus Disclosures Consultancy and speaking fees for Gilead, related to development
More informationName of Policy: Zoledronic Acid (Reclast ) Injection
Name of Policy: Zoledronic Acid (Reclast ) Injection Policy #: 355 Latest Review Date: May 2011 Category: Pharmacy Policy Grade: Active Policy but no longer scheduled for regular literature reviews and
More informationChau Nguyen, D.O. Rheumatologist Clinical Assistant Professor of Internal Medicine at Western University of Health Sciences
Chau Nguyen, D.O Rheumatologist Clinical Assistant Professor of Internal Medicine at Western University of Health Sciences I do not have any relationship with the manufacturer of any commercial products
More informationOsteoporosis/Fracture Prevention Clinical Practice Guidelines
NATIONAL CLINICAL PRACTICE GUIDELINES Osteoporosis/Fracture Prevention Clinical Practice Guidelines Reviewed/Approved by the National Guideline Directors September 2017 Next Review/Approval: September
More informationBREAST CANCER AND BONE HEALTH
BREAST CANCER AND BONE HEALTH Rowena Ridout, MD, FRCPC Toronto Western Hospital Osteoporosis Program University Health Network / Mount Sinai Hospital rowena.ridout@uhn.ca None to declare Conflicts of Interest
More informationNICE SCOOP OF THE DAY FRAX with NOGG. Eugene McCloskey Professor of Adult Bone Diseases University of Sheffield
NICE SCOOP OF THE DAY FRAX with NOGG Eugene McCloskey Professor of Adult Bone Diseases University of Sheffield Disclosures Consultant/Advisor/Speaker for: o ActiveSignal, Amgen, AstraZeneca, Consilient
More informationOsteoporosis in Men. CME Away India & Sri Lanka March 23 - April 7, 2018
Osteoporosis in Men CME Away India & Sri Lanka March 23 - April 7, 2018 Richard A. Bebb MD, ABIM, FRCPC Consultant Endocrinologist Medical Subspecialty Institute Cleveland Clinic Abu Dhabi Copyright 2017
More information